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dative stress, membrane disruption, failures in energy metabolism and
neuronal injury, among other pathological processes.
In the current issue of EBioMedicine, Orešič et al. (2016) describe the
application of a metabolomic platform based on bi-dimensional gas
chromatography coupled to high-resolution mass spectrometry (GC ×
GC-TOF-MS) to identify biomarkers in serum samples that could associ-Medium chain fatty acids
Metabolomics
Traumatic brain injuryTraumatic brain injury (TBI) is a complex disorder with variable eti-
ology and severity that nowadays stands as a major cause of death and
disability worldwide, principally among children and young people. De-
spite the implementation of intensive care strategies at early stages fol-
lowing the injury, long-term morbidity of severe TBI still remains high,
andmany patients may show signiﬁcant neurologic sequelae even after
recovery, which usually persist for years. For this reason, there is a crit-
ical need to get a deeper insight into pathologicalmechanisms occurring
in brain after trauma and discover potential biomarkers that could help
in diagnosis, staging disease severity, monitoring disease progression,
the identiﬁcation of complications, as well as the development of better
strategies for treatment and rehabilitation after injury. TBI pathology
begins with a mechanical brain damage, which is followed by complex
and dynamic perturbations in multiple molecular pathways in glia and
neurons. Thus, holistic approaches such as metabolomics stand out as
suitable tools for characterizing these metabolic alterations. Metabolo-
mics can be deﬁned as the comprehensive study of the entire set of me-
tabolites from a cell, tissue, organ, body ﬂuid or organism at a speciﬁc
time, as well as of the metabolic changes observed in response to a ge-
netic or environmental perturbation. However, only a few authors
have previously reported the application of metabolomic techniques
for investigating TBI pathogenesis, usually by employing nuclear mag-
netic resonance (1H-NMR) to study the brain and blood metabolome
from different animal models (Viant et al., 2005; Bahado-Singh et al.,
2016a; Bahado-Singh et al., 2016b). Thereby, it was demonstrated thatm.2016.07.015.
. This is an open access article undernumerous signiﬁcant disturbances in TBI might be associated with oxi-
ate with disease severity and predict the outcomes of TBI patients. For
this purpose, two independent cohorts were enrolled with the aim to
validate results obtained in the discovery phase, comprisingmild, mod-
erate and severe TBI patients as well as orthopedic controls. Various
metabolomic alterations were detected in serum samples, following
the samepattern in all patients butwith a proportional degree of change
depending on the disease severity, thus suggesting that TBI is character-
ized by a speciﬁc metabotype. Moreover, some of these metabolites
could be also associated with patient clinical outcomes, which were
then employed to build a predictive model with good accuracy. Signiﬁ-
cant changes were observed in serum levels of different hydroxyl-acids,
sugar-derived metabolites as well as amino acids and related com-
pounds. Furthermore,many of thesemetaboliteswere highly correlated
with their content in brain microdialysates, thus evidencing a possible
disruption of the blood brain barrier. However, the most relevant ﬁnd-
ingwas the increase of twomedium chain fatty acids (MCFA), including
octanoic and decanoid acids, whose levels remain high in most patients
during the ﬁrst week following the injury, and could be associated with
poor outcomes in TBI patients. The accumulation of MCFAs, together
with their corresponding acyl-carnitines, is the typical feature of medi-
um-chain acyl-coenzyme A dehydrogenase deﬁciency, the most fre-
quent fatty acid oxidation disorder, and one of the most recognizable
inborn errors of metabolism (Rinaldo and Matern, 2002). Nevertheless,
recent studies have also associated this metabolic signature with other
heterogeneous diseases, such as Alzheimer's disease (González-
Domínguez et al., 2014), schizophrenia (Liu et al., 2014) and different
types of cancer (Hori et al., 2011; Crotti et al., 2016), all of them charac-
terized by impaired mitochondrial function. Furthermore, it has been
demonstrated that these fatty acids can provoke signiﬁcant failures in
various pathways related to energymetabolism, including the oxidative
phosphorylation and the creatine kinase system, and may elicit lipid
and protein oxidative damage (Schuck et al., 2009). Thereby, there is
considerable evidence that suggests the potential of these circulating
MCFAs as biomarkers of mitochondrial dysfunction.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
9R. González-Domínguez / EBioMedicine 12 (2016) 8–9Therefore, it is noteworthy that octanoic and decanoic acids could
play a major role in energy crisis associated withmitochondrial failures
occurring in traumatic brain injury. However, it remains unclear if these
metabolic changes are causative performers of the pathophysiology ob-
served or, on the contrary, they are a consequence of these impairments.
Thus, a better understanding of pathological mechanisms underlying to
these perturbations is necessary to obtain a deeper knowledge about
the relationships between TBI and medium-chain fatty acids. To
this end, future studies should be undertaken with complementary
metabolomic approaches such as reversed phase liquid chromatogra-
phy-mass spectrometry in order to elucidate the relevance of lipid me-
tabolism and fatty acid β-oxidation in pathogenesis of traumatic brain
injury.
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